How many Tirzepatide clinical trials are there?

190 Tirzepatide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 63 are actively recruiting participants. 68 are marked completed.

Are Tirzepatide clinical trials recruiting in 2026?

Yes — 63 Tirzepatide trials are actively recruiting in 2026, with 394 U.S. sites across 42 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Tirzepatide being studied for?

Tirzepatide is being studied for Obesity, Overweight, Type 2 Diabetes, Diabetes Mellitus, Type 2, Healthy and 166 more. The trials are grouped by indication on this page.

What phase is Tirzepatide in?

Tirzepatide clinical trials span 31 Phase 4, 42 Phase 3, 51 Phase 2, 28 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Tirzepatide clinical trials?

The lead sponsor across the most Tirzepatide trials is Eli Lilly and Company, with 89 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Tirzepatide Clinical Trials (2026): 190 Studies for Obesity & Overweight

Creator: Hipa.ai Research
Published: 2026-05-08T18:53:51.742Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

190 Tirzepatide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 77 indications (including Obesity & Overweight) and 1,260,476 total planned enrollment. 42 Phase 3 Tirzepatide trials and 51 Phase 2, 31 Phase 4 are listed. 88 Tirzepatide clinical trials are actively recruiting at 394 U.S. sites across 42 states. Most recent activity: NCT06191848 (May 2037).

Where to Participate: All Tirzepatide Trial Sites in the U.S. (394 sites across 42 states)

Every actively recruiting Tirzepatidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	Digestive Health Specialists	Dothan36301	NCT06937086	Map
AL	Digestive Health Specialists	Dothan36301	NCT06937099	Map
AL	MFA Clinical Research	Tuscaloosa35405	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale	Avondale85392	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Chandler	Chandler85225	NCT06864026	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Chandler	Chandler85224	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Mesa	Chandler85225	NCT06143956	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Flagstaff	Flagstaff86001	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Gilbert	Gilbert85297	NCT06864026	Map
AZ	Spectrum Research Institute	Gilbert85297	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale	Glendale85306	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Mesa	Mesa85210	NCT06864026	Map
AZ	The Institute for Liver Health II dba Arizona Liver Health - Peoria	Peoria85381	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV	Phoenix85032	NCT06864026	Map
AZ	HOPE Research Institute	Phoenix85032	NCT06143956	Map
AZ	Medical Dermatology Specialists	Phoenix85006	NCT06857942	Map
AZ	Headlands Research - Scottsdale	Scottsdale85260	NCT06143956	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Sun City	Sun City85351	NCT06864026	Map
AZ	Epic Medical Research-Sun City	Sun City85351	NCT07165028	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson	Tucson85704	NCT06864026	Map
AZ	AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Tucson Southeast	Tucson85748	NCT06864026	Map
AZ	Del Sol Research Management, LLC	Tucson85715	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Clinical Trials - Tucson	Tucson85712	NCT07165028	Map
AZ	The Institute for Liver Health II dba Arizona Liver Health-Tucson	Tucson85712	NCT06143956	Map
AR	Arkansas Gastroenterology - North Little Rock	North Little Rock72117	NCT07165028	Map
CA	Smart Cures Clinical Research	Anaheim92806	NCT06937086	Map
CA	Smart Cures Clinical Research	Anaheim92806	NCT06937099	Map
CA	Medvin Clinical Research - Apple Valley	Apple Valley92307	NCT06864026	Map
CA	San Fernando Valley Health Institute	Canoga Park91304	NCT07165028	Map
CA	Medvin Clinical Research - Covina	Covina91722	NCT06864026	Map
CA	City of Hope Medical Center	Duarte91010	NCT07202247	Map
CA	Ark Clinical Research - Fountain Valley	Fountain Valley92708	NCT07165028	Map
CA	First OC Dermatology Research Inc	Fountain Valley92708	NCT06857942	Map
CA	Center For Dermatology Clinical Research, Inc.	Fremont94538	NCT06857942	Map
CA	Fresno Clinical Research Center	Fresno93720	NCT07165028	Map
CA	NorCal Medical Research, Inc	Greenbrae94904	NCT06143956	Map
CA	Newport Huntington Medical Group	Huntington Beach92648	NCT06864026	Map
CA	Velocity Clinical Research, Huntington Park	Huntington Park90255	NCT06143956	Map
CA	UCSD - Altman Clinical and Translational Research Institute (ACTRI)	La Jolla92037	NCT07165028	Map
CA	Purushotham & Akther Kotha MD, Inc	La Mesa91942	NCT06864026	Map
CA	Orange County Research Center	Lake Forest92630	NCT07165028	Map
CA	Om Research LLC	Lancaster93534	NCT07165028	Map
CA	Ark Clinical Research	Long Beach90815	NCT07165028	Map
CA	United Medical Doctors - Los Alamitos	Los Alamitos90720	NCT06937086	Map
CA	United Medical Doctors - Los Alamitos	Los Alamitos90720	NCT06937099	Map
CA	Keck School of Medicine, University of Southern California	Los Angeles90032	NCT06994338	Map
CA	Los Angeles Institute for Metabolic Research	Los Angeles90015	NCT07165028	Map
CA	Metropolis Dermatology	Los Angeles90017	NCT06857942	Map
CA	United Medical Doctors - Murrieta	Murrieta92563	NCT07165028	Map
CA	California Medical Research Associates	Northridge91324	NCT06937086	Map
CA	California Medical Research Associates	Northridge91324	NCT06937099	Map
CA	Northridge Clinical Trials	Northridge91325	NCT06857942	Map
CA	Knowledge Research Center	Orange92868	NCT07165028	Map
CA	Clinical and Translational Research Unit	Palo Alto94305	NCT05912621	Map
CA	Stanford University	Palo Alto94304	NCT06657209	Map
CA	California Liver Research Center	Pasadena91105	NCT07165028	Map
CA	Artemis Institute for Clinical Research	Riverside92503	NCT07165028	Map
CA	Medvin Clinical Research - Riverside	Riverside92508	NCT06864026	Map
CA	Peninsula Research Associates	Rolling Hills Estates90274	NCT06143956	Map
CA	Medical Associates Research Group	San Diego92123	NCT07165028	Map
CA	Rheumatology Center of San Diego	San Diego92128	NCT06864026	Map
CA	Quest Clinical Research	San Francisco94115	NCT07165028	Map
CA	Providence Saint John's Medical Foundation	Santa Monica90404	NCT06864026	Map
CA	Medvin Clinical Research - Temecula	Temecula92592	NCT06864026	Map
CA	Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)	Torrance90502	NCT05708859	Map
CA	Medvin Clinical Research - Tujunga	Tujunga91042	NCT06864026	Map
CA	Diablo Clinical Research, Inc.	Walnut Creek94598	NCT06143956	Map
CA	Medvin Clinical Research - Whittier	Whittier90602	NCT06864026	Map
CO	University of Colorado - Anschutz Medical Campus	Aurora80045	NCT06582875	Map
CO	University of Colorado Anschutz Medical Campus	Aurora80045	NCT07165028	Map
CO	South Denver Gastroenterology	Englewood80113	NCT07165028	Map
CT	Stamford Therapeutics Consortium	Stamford06905	NCT06143956	Map
FL	K2 Medical Research WINTER GARDEN	Clermont34711	NCT07165028	Map
FL	K2 Medical Research - Daytona Beach	Daytona Beach32114	NCT07165028	Map
FL	Care Access - Delray Beach	Delray Beach33484	NCT07165028	Map
FL	AMR Clinical	Doral33172	NCT07165028	Map
FL	Northeast Research Institute (NERI)	Fleming Island32003	NCT06143956	Map
FL	Southwest General Healthcare Center	Fort Myers33907	NCT07165028	Map
FL	Indago Research & Health Center, Inc	Hialeah33012	NCT06143956	Map
FL	NeoClinical Research	Hialeah33016	NCT06857942	Map
FL	Encore Medical Research	Hollywood33024	NCT06857942	Map
FL	Encore Medical Research	Hollywood33024	NCT07165028	Map
FL	Skin Care Research	Hollywood33021	NCT06857942	Map
FL	Nature Coast Clinical Research - Inverness	Inverness34452	NCT07165028	Map
FL	Encore Borland-Groover Clinical Research	Jacksonville32256	NCT07165028	Map
FL	Gateway Community Services	Jacksonville32204	NCT06651177	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT07218445	Map
FL	Health Awareness	Jupiter33458	NCT07165028	Map
FL	Vida Clinical Research	Kissimmee34741	NCT06864026	Map
FL	K2 MEDICAL Research THE VILLAGES	Lady Lake32159	NCT07165028	Map
FL	Florida Research Institute	Lakewood Rch34211	NCT07165028	Map
FL	Tampa Bay Medical Research - Largo	Largo33777	NCT07165028	Map
FL	Life Clinical Trials	Margate33063	NCT06864026	Map
FL	Evolution Clinical Trials	Miami33122-1722	NCT07165028	Map
FL	Gastro Health Research - Miami	Miami33176	NCT06937086	Map
FL	Gastro Health Research - Miami	Miami33176	NCT06937099	Map
FL	New Horizon Research Center	Miami33165	NCT06143956	Map
FL	Research Associates of South Florida - Miami - Southwest 8th Street	Miami33134	NCT06937086	Map
FL	Research Associates of South Florida - Miami - Southwest 8th Street	Miami33134	NCT06937099	Map
FL	University of Miami	Miami33136	NCT06774079	Map
FL	CZ Rheumatology	Miami Beach33140	NCT06864026	Map
FL	Floridian Clinical Research, LLC	Miami Lakes33016-1518	NCT07165028	Map
FL	GI PROS Research	Naples34102	NCT07165028	Map
FL	Suncoast Clinical Research, Inc.	New Port Richey34652	NCT06143956	Map
FL	Charter Research - Orlando	Orlando32803	NCT07165028	Map
FL	Charter Research - Winter Park	Orlando32803	NCT06143956	Map
FL	Digestive and Liver Center of Florida	Orlando32825	NCT06937086	Map
FL	Digestive and Liver Center of Florida	Orlando32825	NCT06937099	Map
FL	Headlands Research Orlando	Orlando32806	NCT07165028	Map
FL	Orlando Health	Orlando32806	NCT06937086	Map
FL	Orlando Health	Orlando32806	NCT06937099	Map
FL	Vitalia Medical Research	Palm Beach Gardens33410	NCT06864026	Map
FL	Gastro Health Research - Pensacola	Pensacola32504	NCT06937086	Map
FL	Gastro Health Research - Pensacola	Pensacola32504	NCT06937099	Map
FL	Progressive Medical Research	Port Orange32127	NCT07165028	Map
FL	Covenant Metabolic Specialists - Riverview	Riverview33578	NCT07165028	Map
FL	Care Access - St. Petersburg	St. Petersburg33710	NCT07165028	Map
FL	Precision Clinical Research	Sunrise33351	NCT06937086	Map
FL	Precision Clinical Research	Sunrise33351	NCT06937099	Map
FL	Care Access - Tamarac	Tamarac33321	NCT07165028	Map
FL	International Center for Research	Tampa33614	NCT06864026	Map
FL	MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research	Tampa33607	NCT06857942	Map
FL	Charter Research - Lady Lake	The Villages32162	NCT06143956	Map
FL	Covenant Metabolic Specialists, LLC	University Park34201	NCT07165028	Map
FL	TruDerm & TruSpa	Wellington33449	NCT06857942	Map
GA	Southeast Clinical Research Center	Dalton30720	NCT07165028	Map
GA	CenExel iResearch, LLC	Decatur30030	NCT06439277	Map
GA	Southeast Research Specialists	Douglasville30135	NCT06857942	Map
GA	Atlanta Research Center for Rheumatology	Marietta30060	NCT06864026	Map
GA	Gastrointestinal Specialists of Georgia	Marietta30060	NCT07165028	Map
GA	Rophe Adult and Pediatric Medicine/SKYCRNG	Union City30291	NCT07165028	Map
GA	Satilla Rheumatology & Internal Medicine	Waycross31501	NCT06864026	Map
HI	John A Burns School of Medicine	Honolulu96813	NCT06935838	Map
HI	Pacific Diabetes & Endocrine Center	Honolulu96817	NCT06143956	Map
ID	Medical Research Partners	Ammon83406	NCT06143956	Map
ID	Grand Teton Research Group	Idaho Falls83404	NCT06937086	Map
ID	Grand Teton Research Group	Idaho Falls83404	NCT06937099	Map
IL	Great Lakes Clinical Trials - Ravenswood	Chicago60640	NCT06143956	Map
IL	Great Lakes Clinical Trials - Ravenswood	Chicago60640	NCT06864026	Map
IL	Rush University Medical Center	Chicago60612	NCT06937086	Map
IL	Ruth M. Rothstein CORE Center	Chicago60612	NCT06651177	Map
IL	Greater Chicago Specialty Physicians	Schaumburg60195	NCT06864026	Map
IL	Arnold Arthritis & Rheumatology	Skokie60076	NCT06864026	Map
IL	NorthShore University Health System	Skokie60077	NCT06143956	Map
IL	Willow Rheumatology and Wellness PLLC	Willowbrook60527	NCT06864026	Map
IN	Dawes Fretzin Clinical Research Group, LLC	Indianapolis46250	NCT06857942	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06937086	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06937099	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT07165028	Map
IN	Gastroenterology Health Partners	New Albany47150	NCT06937086	Map
IN	Gastroenterology Health Partners	New Albany47150	NCT06937099	Map
IN	Lake Cumberland Rheumatology	New Albany47150	NCT06864026	Map
IN	Deaconess Clinic- Gateway	Newburgh47630	NCT07165028	Map
IN	The Indiana Clinical Trials Center, PC	Plainfield46168	NCT06857942	Map
IN	Digestive Research Alliance of Michiana	South Bend46635	NCT07165028	Map
IA	Iowa Diabetes and Endocrinology Research Center	West Des Moines50266	NCT06143956	Map
IA	Iowa Diabetes and Endocrinology Research Center	West Des Moines50266	NCT07165028	Map
KS	AMR Clinical	El Dorado67042	NCT07165028	Map
KS	Johnson County Clinical Trials	Lenexa66219	NCT07165028	Map
KS	Cotton O'Neil Diabetes & Endocrinology	Topeka66606	NCT06143956	Map
KS	Cotton O'Neil Digestive Health Center	Topeka66606	NCT07165028	Map
KY	Equity Medical - Bowling Green	Bowling Green42104	NCT06857942	Map
KY	AMR Clinical	Lexington40509	NCT07165028	Map
KY	University of Kentucky	Lexington40506	NCT06721507	Map
KY	Gastroenterology Health Partners	Louisville40218	NCT06937086	Map
KY	Gastroenterology Health Partners	Louisville40218	NCT06937099	Map
KY	Monroe Biomedical Research - Louisville	Louisville40213	NCT06143956	Map
LA	Delta Research Partners of Bastrop, LLC	Bastrop71220	NCT07165028	Map
LA	Pennington Biomedical Research Center	Baton Rouge70808	NCT07154719	Map
LA	Accurate Clinical Research, Inc	Lake Charles70605	NCT06864026	Map
LA	Tandem Clinical Research	Marrero70072	NCT07165028	Map
LA	Care Access - New Iberia	New Iberia70560	NCT06937086	Map
LA	Care Access - New Iberia	New Iberia70560	NCT06937099	Map
LA	Care Access - New Iberia	New Iberia70560	NCT07165028	Map
LA	Louisiana Research Center	Shreveport71105	NCT06937086	Map
LA	Louisiana Research Center	Shreveport71105	NCT06937099	Map
LA	Louisiana Research Center	Shreveport71105	NCT07165028	Map
LA	Delta Research Partners of West Monroe	West Monroe71291	NCT07165028	Map
MD	Johns Hopkins University	Baltimore21146	NCT06847399	Map
MD	Mercy Medical Center - Baltimore	Baltimore21202	NCT07165028	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07046819	Map
MD	National Institutes of Health Clinical Center	Bethesda20892	NCT07559500	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT06937086	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT06937099	Map
MD	Capital Digestive Care - Chevy Chase	Chevy Chase20815	NCT07165028	Map
MD	Klein & Associates, M.D., P.A.	Cumberland21502	NCT06864026	Map
MD	Klein & Associates, M.D., P.A.	Hagerstown21740	NCT06864026	Map
MD	Dermatology and Skin Cancer Specialists, LLC	Rockville20850	NCT06857942	Map
MA	Massachusetts General Hospital	Boston02114	NCT05933499	Map
MA	Massachusetts General Hospital Cancer Center	Boston02114	NCT07095517	Map
MA	Metro Boston Clinical Partners	Brighton02135	NCT06857942	Map
MA	Brigham and Women's Faulkner Hospital	Jamaica Plain02130	NCT06727331	Map
MA	Knownwell	Needham02492	NCT06143956	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06143956	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06937086	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT06937099	Map
MA	Lucida Clinical Trials	New Bedford02740	NCT07165028	Map
MI	David Fivenson, MD, PLC	Ann Arbor48103	NCT06857942	Map
MI	University of Michigan	Ann Arbor48109	NCT07091734	Map
MI	Great Lakes Research Group, Inc.	Bay City48706	NCT06857942	Map
MI	The Derm Institute of West Michigan	Caledonia49316	NCT06857942	Map
MI	Clinical Research Institute of Michigan, LLC	Clinton Township48038	NCT07165028	Map
MI	Clinical Research Institute of Michigan, LLC	Saint Clair Shores48081	NCT06864026	Map
MI	Great Lakes Research Institute	Southfield48075	NCT07165028	Map
MI	Headlands Research - Detroit	Southfield48034	NCT06143956	Map
MI	Arcturus Healthcare , PLC, Troy Internal Medicine Research Division	Troy48098	NCT06143956	Map
MI	Arcturus Healthcare , PLC, Troy Internal Medicine Research Division	Troy48098	NCT07165028	Map
MN	MNGI Digestive Health	Minneapolis55413	NCT07165028	Map
MN	Children's Minnesota	Saint Paul55102	NCT06901245	Map
MS	GI Associates - GIA and Endoscopy Center - Flowood	Flowood39232	NCT07165028	Map
MO	The Gibson Center for Behavioral Change	Cape Girardeau63703	NCT06651177	Map
MO	StudyMetrix Research	City of Saint Peters63303	NCT06143956	Map
MO	AMR Clinical	Kansas City64114	NCT07165028	Map
MO	Clinvest Headlands Llc	Springfield65807	NCT06143956	Map
MO	Washington University School of Medicine	St Louis63110	NCT06937086	Map
MO	Washington University School of Medicine	St Louis63110	NCT06937099	Map
MO	Washington University School of Medicine	St Louis63110	NCT06976853	Map
MT	Logan Health Rheumatology	Kalispell59901	NCT06864026	Map
NV	Excel Clinical Research, LLC	Las Vegas89109	NCT07165028	Map
NV	Jubilee Clinical Research NV. LLC	Las Vegas89106	NCT07165028	Map
NV	Las Vegas Medical Research	Las Vegas89128	NCT06143956	Map
NV	Skin Cancer and Dermatology Institute - Reno	Reno89509	NCT06857942	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT06937086	Map
NH	Dartmouth-Hitchcock Medical Center	Lebanon03756	NCT06937099	Map
NH	Stracskin	Portsmouth03801	NCT06857942	Map
NJ	Memorial Sloan Kettering Basking Ridge	Basking Ridge07920	NCT06751589	Map
NJ	Psoriasis Treatment Center of Central New Jersey	East Windsor08520	NCT06857942	Map
NJ	Trinitas Comprehensive Cancer Center	Elizabeth07202	NCT06518837	Map
NJ	Tandem Clinical Research - Freehold	Freehold07728	NCT07165028	Map
NJ	Care Access - Hoboken	Hoboken07030	NCT06857942	Map
NJ	RWJBarnabas Health - Cooperman Barnabas, Livingston	Livingston07039	NCT06518837	Map
NJ	RWJBarnabas Health - Monmouth Medical Center	Long Branch07740	NCT06518837	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06751589	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06751589	Map
NJ	Rutgers Cancer Institute	New Brunswick08901	NCT06518837	Map
NJ	RWJBarnabas Health - Newark Beth Israel Medical Center	Newark07112	NCT06518837	Map
NJ	Clinical Research of Philadelphia	Pennington08534	NCT07165028	Map
NJ	The Cognitive and Research Center of New Jersey - Ridgewood	Ridgewood07450	NCT07165028	Map
NJ	RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset	Somerville08876	NCT06518837	Map
NJ	IMA Clinical Research Warren	Warren Township07059	NCT07165028	Map
NM	Southwest Gastroenterology Associates	Albuquerque87109	NCT07165028	Map
NM	University of New Mexico Health Sciences Center	Albuquerque87131	NCT06934642	Map
NY	Dent Neurologic Institute	Amherst14226	NCT06143956	Map
NY	Research Foundation of SUNY - University of Buffalo	Buffalo14203	NCT07165028	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06751589	Map
NY	Velocity Clinical Research, Syracuse	East Syracuse13057	NCT06143956	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06751589	Map
NY	Equity Medical	New York10023	NCT06857942	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06937086	Map
NY	Icahn School of Medicine at Mount Sinai	New York10029	NCT06976853	Map
NY	IMA Clinical Research Manhattan	New York10036	NCT07165028	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06751589	Map
NY	New York Gastroenterology Associates	New York10075	NCT06937086	Map
NY	New York Gastroenterology Associates	New York10075	NCT06937099	Map
NY	New York Gastroenterology Associates	New York10075	NCT07165028	Map
NY	North Suffolk Neurology	Port Jefferson Station11776	NCT06143956	Map
NY	Rochester Clinical Research, LLC	Rochester14609	NCT06143956	Map
NY	University of Rochester Medical Center	Rochester14642	NCT06864026	Map
NY	Memorial Sloan Kettering Nassau	Uniondale11553	NCT06751589	Map
NY	Care Access - Yonkers	Yonkers10701	NCT06937086	Map
NY	Care Access - Yonkers	Yonkers10701	NCT06937099	Map
NY	Care Access - Yonkers	Yonkers10701	NCT07165028	Map
NC	Revival Research Institute, LLC	Cary27511	NCT06857942	Map
NC	Lineberger Comprehensive Cancer Center	Chapel Hill27599	NCT07065552	Map
NC	Coastal Research Institute - Fayetteville	Fayetteville28304	NCT06937086	Map
NC	Coastal Research Institute - Fayetteville	Fayetteville28304	NCT06937099	Map
NC	Medication Management	Greensboro27405	NCT06143956	Map
NC	Onsite Clinical Solutions - Huntersville	Huntersville28078	NCT06857942	Map
NC	Monroe Biomedical Research	Monroe28112	NCT06143956	Map
NC	Monroe Biomedical Research	Monroe28112	NCT07165028	Map
NC	Carteret Medical Group	Morehead City28557	NCT07165028	Map
NC	Lucas Research, Inc	Morehead City28557	NCT06143956	Map
NC	Lucas Research, Inc.	New Bern28562	NCT06143956	Map
NC	Onsite Clinical Solutions, LLC - Brenner Ave	Salisbury28144	NCT06864026	Map
OH	Akron Gastro Research	Akron44320	NCT07165028	Map
OH	Optima Research - Boardman	Boardman44512	NCT06857942	Map
OH	CTI Clinical Research Center	Cincinnati45212	NCT06143956	Map
OH	Cleveland Clinic	Cleveland44195	NCT06802081	Map
OH	Paramount Medical Research & Consulting, LLC	Middleburg Heights44130	NCT06864026	Map
OH	CRIOH	Westlake44145	NCT07165028	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC	Westlake44145	NCT06937086	Map
OH	Gastro Intestinal Research Institute of Northern Ohio, LLC	Westlake44145	NCT06937099	Map
OK	Essential Medical Research	Tulsa74137	NCT06864026	Map
OR	Oregon Dermatology and Research Center	Portland97210	NCT06857942	Map
PA	US Digestive Health - Flourtown	Flourtown19031	NCT07165028	Map
PA	Thomas Jefferson University - Medicine/GI and Hepatology	Philadelphia19107	NCT06937086	Map
PA	Thomas Jefferson University - Medicine/GI and Hepatology	Philadelphia19107	NCT06937099	Map
PA	Dermatology Associates of Plymouth Meeting	Plymouth Meeting19462	NCT06857942	Map
PA	US Digestive Health - Wyomissing	Wyomissing19610	NCT07165028	Map
RI	University Gastroenterology	Providence02905	NCT06937086	Map
RI	University Gastroenterology	Providence02905	NCT06937099	Map
RI	University Gastroenterology	Providence02905	NCT07165028	Map
SC	Columbia Dermatology & Aesthetics	Columbia29212	NCT06857942	Map
SC	Columbia Digestive Health Research	Columbia29204	NCT07165028	Map
SC	Gastroenterology Associates - Patewood	Greenville29607	NCT06937086	Map
SC	Gastroenterology Associates - Patewood	Greenville29607	NCT06937099	Map
SC	Prisma Health	Greenville29605	NCT06651177	Map
SC	Tribe Clinical Research, LLC	Greenville29607	NCT06143956	Map
TN	Galen Medical Group - Galen Hepatology	Chattanooga37421	NCT07165028	Map
TN	Gastro One (Walnut Run Road)	Cordova38018	NCT07165028	Map
TN	Gastroenterology Center Of The Midsouth	Cordova38018	NCT06937086	Map
TN	Gastroenterology Center Of The Midsouth	Cordova38018	NCT06937099	Map
TN	West Tennessee Research Institute	Jackson38305	NCT06864026	Map
TN	St. Jude Children's Research Hospital	Memphis38105	NCT07228741	Map
TN	AARA Clinical Research - Murfreesboro Medical Clinic	Murfreesboro37128	NCT06864026	Map
TN	Quality Medical Research	Nashville37211	NCT06143956	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT06651177	Map
TN	Vanderbilt University Medical Center	Nashville37203	NCT06901245	Map
TN	DelRicht Research - Thompson's Station	Smyrna37167	NCT06857942	Map
TX	American Research Corporation	Austin78757	NCT07165028	Map
TX	IMA Clinical Research Austin	Austin78745	NCT06143956	Map
TX	IMA Clinical Research Austin	Austin78745	NCT07165028	Map
TX	Pinnacle Clinical Research	Austin78757	NCT07165028	Map
TX	Bellaire Clinical Research	Bellaire77401	NCT07165028	Map
TX	Bellaire Dermatology Associates	Bellaire77401	NCT06857942	Map
TX	Headlands Horizons, LLC dba Headlands Research-Brownsville	Brownsville78526	NCT07165028	Map
TX	South Texas Research Institute - Brownsville	Brownsville78520	NCT07165028	Map
TX	Precision Comprehensive Clinical Research Solutions - Colleyville	Colleyville76034	NCT06864026	Map
TX	Baylor University Medical Center, Baylor Charles A Sammons Cancer Center	Dallas75246	NCT06517212	Map
TX	FutureSearch Trials of Dallas	Dallas75251	NCT06143956	Map
TX	Modern Research Associates, PLLC	Dallas75231	NCT06857942	Map
TX	Velocity Clinical Research, Dallas	Dallas75230	NCT06143956	Map
TX	Soma Clinical Trials	Denison75020	NCT07165028	Map
TX	Epic Medical Research - DeSoto	DeSoto75115	NCT07165028	Map
TX	South Texas Research Institute	Edinburg78539	NCT07165028	Map
TX	Dallas Research Institute	Farmers Branch75234	NCT07165028	Map
TX	Care United Research, LLC	Forney75126	NCT07165028	Map
TX	AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Fort Worth	Fort Worth76109	NCT06864026	Map
TX	GI Alliance - Fort Worth	Fort Worth76104	NCT07165028	Map
TX	Accurate Clinical Research, Inc	Houston77089	NCT06864026	Map
TX	Biopharma Informatic, LLC	Houston77084	NCT07165028	Map
TX	Care Access - Houston	Houston77054	NCT07165028	Map
TX	Center for Clinical Studies	Houston77004	NCT06857942	Map
TX	Houston Research Institute	Houston77079	NCT07165028	Map
TX	HRI- Medical Center	Houston77004	NCT07165028	Map
TX	PlanIt Research, PLLC	Houston77079	NCT06143956	Map
TX	Research Physicians Network, LLC	Houston77089	NCT06864026	Map
TX	Research Physicians Network, LLC	Houston77089	NCT07165028	Map
TX	The University of Texas M. D. Anderson Cancer Center	Houston77030	NCT06759701	Map
TX	AARA Clinical Research - Lone Star Arthritis and Rheumatology Associates - Irving	Irving75039	NCT06864026	Map
TX	Biopharma Informatic, LLC	Katy77494	NCT06864026	Map
TX	Biopharma Informatic, LLC	McAllen78503	NCT07165028	Map
TX	DHR Health Institute for Research and Development (Administrative Office & Laboratory)	McAllen78504	NCT07165028	Map
TX	Southern Endocrinology Associates	Mesquite75149	NCT07165028	Map
TX	HRI Pasadena	Pasadena77505	NCT07165028	Map
TX	Austin Institute for Clinical Research	Pflugerville78660	NCT06857942	Map
TX	American Research Corporation at Texas Liver Institute	San Antonio78215	NCT07165028	Map
TX	Clinical Trials of Texas, LLC dba Flourish Research	San Antonio78229	NCT07165028	Map
TX	Endeavor Clinical Trials	San Antonio78240	NCT06143956	Map
TX	Gastroenterology Research of San Antonio	San Antonio78229	NCT06937086	Map
TX	Gastroenterology Research of San Antonio	San Antonio78229	NCT06937099	Map
TX	IMA Clinical Research San Antonio	San Antonio78229	NCT07165028	Map
TX	Southern Star Research Institute	San Antonio78229	NCT06937086	Map
TX	Southern Star Research Institute	San Antonio78229	NCT06937099	Map
TX	Tekton Research - Fredericksburg Road	San Antonio78258	NCT06143956	Map
TX	Texas Dermatology and Laser Specialists	San Antonio78218	NCT06857942	Map
TX	University Health System Texas Diabetic Institute	San Antonio78207	NCT06246799	Map
TX	University of Texas Health Science Center at San Antonio	San Antonio78229	NCT06811324	Map
TX	UT Health Science Center	San Antonio78229	NCT06246799	Map
TX	Consano Clinical Research, LLC	Shavano Park78231	NCT07165028	Map
TX	GI Alliance - Southlake	Southlake76092	NCT07165028	Map
TX	Houston Research Institute (HRI) - Sugar Land	Sugar Land77479	NCT07165028	Map
TX	Advanced Rheumatology of Houston - Woodlands	The Woodlands77382	NCT06864026	Map
TX	DM Clinical Research - TRA	Tomball77375	NCT06864026	Map
TX	Tyler Research Institute	Tyler75701	NCT06937086	Map
TX	Tyler Research Institute	Tyler75701	NCT06937099	Map
TX	Center for Clinical Studies	Webster77598	NCT06857942	Map
TX	Texas Valley Clinical Research	Weslaco78596	NCT06143956	Map
TX	Texas Valley Clinical Research	Weslaco78596	NCT07165028	Map
TX	Medrasa Clinical Research	Wylie75098	NCT07165028	Map
UT	Tanner Clinic	Layton84041	NCT06857942	Map
UT	Care Access - Ogden	Ogden84403	NCT07165028	Map
UT	University of Utah	Salt Lake City84108	NCT06651177	Map
UT	Advanced Research Institute - Sandy	Sandy City84070	NCT07165028	Map
VA	Sovah Clinical Research-River District	Danville24541	NCT06143956	Map
VA	Eximia Research - Norfolk	Norfolk23502	NCT07165028	Map
VA	Richmond Veterans Affairs Medical Center (Richmond VA Medical Center)	Richmond23249	NCT07165028	Map
VA	Gastroenterology Consultants of Southwest Virginia	Roanoke24014	NCT06937086	Map
VA	Gastroenterology Consultants of Southwest Virginia	Roanoke24014	NCT07165028	Map
WA	Bellevue Dermatology Clinic	Bellevue98104	NCT06857942	Map
WA	Washington Gastroenterology - Bellevue	Bellevue98004	NCT07165028	Map
WA	Dermatology of Seattle	Burien98168	NCT06857942	Map
WA	Seattle Children's Hospital	Seattle98105	NCT06901245	Map
WA	Seattle Rheumatology Associates PLLC	Seattle98104	NCT06864026	Map
WA	UW Medicine Diabetes Institute	Seattle98109	NCT07165028	Map
WA	Arthritis Northwest, PLLC	Spokane Valley99216	NCT06864026	Map
WA	Washington Gastroenterology - Tacoma	Tacoma98405	NCT06937086	Map
WA	Washington Gastroenterology - Tacoma	Tacoma98405	NCT06937099	Map
WA	Central Washington Health Services Association d/b/a Confluence Health	Wenatchee98801	NCT06143956	Map
WV	CAMC Health Education and Research Institute Inc	Charleston25304	NCT07165028	Map
WV	Marshall Health	Huntington25701	NCT06651177	Map
WV	Healthy Minds/Chestnut Ridge	Morgantown26505	NCT06651177	Map
WI	Wisconsin Center for Advanced Research	Milwaukee53215	NCT06937086	Map
WI	Wisconsin Center for Advanced Research	Milwaukee53215	NCT06937099	Map

Tirzepatide clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	enrolling by invitation	completed	terminated	withdrawn	not yet recruiting	unknown	Total
Early P1	4								4
P1	3	1		24					28
P1/P2	3	1							4
P2	21	9		6	1	1	12	1	51
P2/P3	1		1						2
P3	7	8		26			1		42
P4	17	4	1	3		1	5		31
N/A	5	4		9		1	7	2	28

Recruiting Tirzepatide clinical trials (88)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06191848	STOP KNEE-OASubcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	P4	Obesity	352	Nov 2024
NCT07165028	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	P3	Metabolic Dysfunction-Associated Steatotic Liver Disease	4,500	Oct 2025
NCT07247084	LY3298176A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)	P4	Obesity	3,000	Nov 2025
NCT07559500	AUDTirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)	P1	Alcohol Use Disorder (AUD)	176	May 2026
NCT06517212	TRIM-EBCTirzepatide Weight Loss for MRD+ Early Breast Cancer	P2	Breast Cancer	48	Nov 2024
NCT06439277	SURMOUNT-ADOLESCENTS-2A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	P3	Obesity	300	Jun 2024
NCT07443956	COMBAT-PsACombination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis	N/A	Psoriatic Arthritis (PsA)	45	Mar 2026
NCT07554638	Incretin Therapies in Obesity-related HFpEF	P4	Heart Failure, Diastolic	50	Jun 2026
NCT07349641	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	P2	Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia	55	Jul 2026
NCT07326111	PERIODSA Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese	P4	Polycystic Ovary Syndrome (PCOS)	198	Dec 2025
NCT05912621	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	P2	Obesity	66	Nov 2023
NCT07527910	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD	P2	Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	204	Apr 2026
NCT07091734	TILT-2024Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024	P2	Lipodystrophy, Partial	32	Sep 2025
NCT06582875	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD	P2	Autosomal Dominant Polycystic Kidney	126	Mar 2025
NCT06246799	Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	P3	Type 2 Diabetes (Adult Onset)	256	Nov 2024
NCT07567378	CARTIZCARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	—	Psoriatic Arthritis	30	May 2026
NCT07078838	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	P2	Endometrial Cancer	40	Aug 2026
NCT05933499	Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity	P2	Obesity	63	Nov 2025
NCT07364175	SOLUTION-PilotA Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults	N/A	Hypertension	60	Jan 2026
NCT07284511	TZPA Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	P2/P3	Type 1 Diabetes	105	May 2026
NCT06180616	TZP-T1DTirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity	P2	Type 1 Diabetes Mellitus	40	Dec 2026
NCT07573163	Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion	P2	Mild Autonomous Cortisol Secretion (MACS)	34	Jul 2026
NCT07095517	PROSPECTPathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	P1	Colorectal Cancer Prevention	20	Feb 2026
NCT06759701	Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study	Early P1	Diabetes	30	Jul 2025
NCT06939088	DUALPSYCHIATRYEffects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	P2	Alcohol Use Disorder	108	May 2025
NCT07309094	ADIPO-CKDClinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	—	Chronic Kidney Disease stage3	250	Sep 2023
NCT07228741	Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity	P2	Acute Lymphoblastic Leukemia	20	Apr 2026
NCT07468552	Trial of Tirzepatide for the Treatment of Cannabis Use Disorder	P2	Cannabis Use Disorder	100	Nov 2026
NCT07555730	AIM-MAINTAINAI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)	P4	Overweight or Obesity; Type 2 Diabetes	400	Apr 2026
NCT06976853	Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease	P2	Crohn Disease (CD)	60	May 2025
NCT07096908	Tirzepatide Use in People With Obesity and Type 1 Diabetes	P4	Type1diabetes	60	Jul 2025
NCT06606821	IDEAL-CORThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	P4	Coronary Artery Disease	124	Oct 2024
NCT07382024	TREAT-AFTirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	N/A	Atrial Fibrillation Ablation	200	May 2026
NCT07065552	Tirzepatide in Obesity-Driven Endometrial Cancer	Early P1	Endometrial Cancer	20	Apr 2026
NCT07265752	Tirzepatide for the Treatment of Cannabis Use Disorder	P2	Cannabis Use Disorder	6	Jul 2026
NCT06937099	COMMIT-CDMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	P3	Crohn's Disease	290	Jun 2025
NCT06857942	LY3298176A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	P4	Psoriasis	200	Mar 2025
NCT07483801	DECODEDECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	P4	Cardiovascular Diseases	112	Mar 2026
NCT06937086	COMMIT-UCMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	P3	Ulcerative Colitis	350	Jun 2025
NCT07202247	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	P2	Prostate Carcinoma	60	Jan 2026
NCT07481747	SURMOUNT-1Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)	P3	Obesity	2,539	Feb 2026
NCT07463846	A Study to Evaluate ALN-2232 in Participants With Obesity	P1/P2	Obesity	156	Mar 2026
NCT07191873	TIIHTTirzepatide in Idiopathic Intracranial Hypertension Trial	P4	Idiopathic Intracranial Hypertension (IIH)	60	Feb 2026
NCT06143956	LY900038A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	P2	Obesity	1,481	Nov 2023
NCT06700538	A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus	P1/P2	Obesity	180	Dec 2024
NCT07292519	CBTTirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	P2	Alcohol Use Disorder (AUD)	46	Jan 2026
NCT06820281	TIRTLE2Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes	P2	Type 1 Diabetes Mellitus	44	Jul 2026
NCT06751589	A Study of a Weight Loss Intervention in People With Endometrial Cancer	Early P1	Endometrial Cancer	36	Dec 2024
NCT07257484	Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors	P4	Obesity (Disorder)	30	Apr 2026
NCT06732245	Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese	P2	Obesity and Overweight	224	Aug 2026
NCT06657209	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	P4	Diabetes Mellitus, Type 2	104	Jan 2025
NCT06847399	LIBERATEEfficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	P2	Obesity and Overweight	105	Sep 2025
NCT06162715	GRABS-0GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	P2/P3	Severe Obesity	30	Oct 2024
NCT06864026	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	P4	Psoriatic Arthritis	200	Mar 2025
NCT07492563	Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	—	Obesity	300	Mar 2026
NCT07438444	LY3298176A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	P4	Diabetes Mellitus, Type 2	344	Feb 2026
NCT06651177	TABEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	P2	Opioid Use Disorder	310	Jan 2026
NCT05553093	Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes	P4	Type 2 Diabetes Mellitus	150	Mar 2022
NCT06518837	FITWISETirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	P2	Hormone Receptor-Positive Breast Cancer	40	Oct 2024
NCT07218445	The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	P4	Obesity	40	Apr 2026
NCT07245771	Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity	P1/P2	Obesity &Amp; Overweight	104	Nov 2025
NCT07521631	Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes	P2	Obesity	372	Mar 2026
NCT07298915	EXER-MEDThe Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)	P3	Obesity & Overweight	24	Aug 2026
NCT07293325	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	N/A	Adults With Simple Obesity	66	Jun 2025
NCT06811324	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	P2	Obesity Prevention	20	Apr 2026
NCT06802081	TIRO-AFTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation	P2	Atrial Fibrillation	100	Apr 2025
NCT07154719	GRAMSGLP-1R Actions on Muscle and the Skeleton	P4	Musculoskeletal Abnormalities	50	Oct 2025
NCT07373834	TIRMOTirzepatide and Muscle Outcomes in Obesity	N/A	Obesity (Disorder)	30	Jan 2026
NCT07057310	Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	P4	Obesity	30	May 2025
NCT06774079	GLP-1 RAGlucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients	P4	Crohn Disease	24	Mar 2025
NCT07179120	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	P2	Obesity-related Male Infertility	180	May 2026
NCT07319975	Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	N/A	Obesity	48	Dec 2025
NCT06901245	Tirzepatide in PWS, HO and GNSO	P4	Prader-Willi Syndrome	36	May 2025
NCT06721507	2024 Tirzepatide-Bariatric Surgery	P4	Obesity and Obesity-related Medical Conditions	50	Mar 2025
NCT07423247	Tirzepatide (Spartina) in Obese Kidney Transplant Recipients	P4	Tirzepatide	30	Jan 2026
NCT06994338	Tirzepatide for Alcohol Use Disorder	P2	Alcohol Use Disorder	42	Oct 2025
NCT06934642	Effect of Tirzepatide on Markers of MASLD in Patients With Obesity	Early P1	MASLD	8	Jun 2025
NCT07504172	TIRZ-DOSE-NLReal-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity	—	Overweight , Obesity	1,700	Apr 2026
NCT06935838	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	P2	Obesity and Overweight	12	Nov 2025
NCT07099742	T2DMEffectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)	—	Obesity	364	Sep 2025
NCT06727331	STREAMStudy of Tirzepatide for Recovery and Alcohol Use Management	P2	Alcohol Use Disorder (AUD)	20	Sep 2025
NCT07046819	Tirzepatide in MetALD	P2	Metabolic Alcohol-associated Liver Disease	120	Apr 2026
NCT06630585	AID-JUNCTGIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes	P3	Type 1 Diabetes (T1D)	42	Feb 2025
NCT05822544	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	P1	Healthy Subjects	564	Apr 2023
NCT06737042	Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants	P2	Obesity and Overweight	285	Feb 2025
NCT05708859	T-PLAQUEEffect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	P4	Type II Diabetes	120	Jan 2024
NCT07176663	TirzepatideEfficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure	N/A	Obesity	15	Feb 2026
NCT06911203	A Study of BGM0504 in Participants With Obesity	P2	Obesity	90	Apr 2025

Tirzepatide clinical trials by indication

Obesity (48)

NCT	Acronym	Phase	Status	Title
NCT06191848	STOP KNEE-OA	P4	recruiting	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT07247084	LY3298176	P4	recruiting	A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT06439277	SURMOUNT-ADOLESCENTS-2	P3	recruiting	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT05912621	—	P2	recruiting	Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
NCT06075667	LY3298176	P3	active not recruiting	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT05933499	—	P2	recruiting	Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity
NCT06801015	—	P4	active not recruiting	Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions
NCT07481747	SURMOUNT-1	P3	recruiting	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
+ 40 more, see All trials below.

Type 2 Diabetes (19)

NCT	Acronym	Phase	Status	Title
NCT05433584	SURPASS-EARLY	P4	active not recruiting	A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
NCT06037252	LY3298176	P2	active not recruiting	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06980623	—	N/A	active not recruiting	Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
NCT07417618	INTERCEPT	N/A	active not recruiting	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
NCT06635057	T-RAM	P4	completed	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
NCT06221969	—	P3	completed	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
NCT06779929	SURPASS CVOT	N/A	completed	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT07088718	DUP-SURPASS	N/A	completed	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data
+ 11 more, see All trials below.

Diabetes Mellitus, Type 2 (9)

NCT	Acronym	Phase	Status	Title
NCT06657209	—	P4	recruiting	Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
NCT07438444	LY3298176	P4	recruiting	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
NCT07299084	—	P1	active not recruiting	A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus
NCT06534411	REIMAGINE 5	P3	active not recruiting	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
NCT06914154	DUP-SUMMIT	N/A	completed	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
NCT06914141	DUP-TIRZSEMA	N/A	completed	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
NCT04050553	—	P1	completed	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
NCT04235959	—	P1	completed	A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus
+ 1 more, see All trials below.

Healthy (9)

NCT	Acronym	Phase	Status	Title
NCT06890611	LY3985863	P1	completed	A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants
NCT05978713	LY3298176	P1	completed	A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
NCT05810597	—	P1	completed	A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
NCT04172987	—	P1	completed	A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
NCT04311424	—	P1	completed	Study of Tirzepatide in Healthy Participants
NCT04050670	—	P1	completed	A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes
NCT04004988	—	P1	completed	A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants
NCT03375463	LY3298176	P1	completed	A Study of Tirzepatide (LY3298176) in Healthy Participants
+ 1 more, see All trials below.

Type 2 Diabetes Mellitus (8)

NCT	Acronym	Phase	Status	Title
NCT05553093	—	P4	recruiting	Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
NCT04255433	SURPASS-CVOT	P3	completed	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
NCT03730662	SURPASS-4	P3	completed	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
NCT03861039	LY3298176	P3	completed	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
NCT03882970	SURPASS-3	P3	completed	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
NCT03954834	SURPASS-1	P3	completed	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
NCT03322631	LY3298176	P1	completed	A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
NCT03131687	LY3298176	P2	completed	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

Overweight (6)

NCT	Acronym	Phase	Status	Title
NCT05536804	TREASURE-CKD	P2	active not recruiting	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT06047548	—	P3	completed	A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06916065	LY3841136	P1	completed	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
NCT04184622	SURMOUNT-1	P3	completed	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
NCT05582096	—	P1	completed	A Study of LY3457263 in Obese Participants
NCT04407234	—	P1	completed	A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

Obesity and Overweight (4)

NCT	Acronym	Phase	Status	Title
NCT06732245	—	P2	not yet recruiting	Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese
NCT06847399	LIBERATE	P2	recruiting	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
NCT06935838	—	P2	recruiting	Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
NCT06737042	—	P2	not yet recruiting	Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

Psoriatic Arthritis (3)

NCT	Acronym	Phase	Status	Title
NCT07567378	CARTIZ	N/A	not yet recruiting	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
NCT06864026	—	P4	recruiting	A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
NCT06588296	TOGETHER-PsA	P3	completed	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Alcohol Use Disorder (AUD) (3)

NCT	Acronym	Phase	Status	Title
NCT07559500	AUD	P1	recruiting	Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
NCT07292519	CBT	P2	not yet recruiting	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)
NCT06727331	STREAM	P2	recruiting	Study of Tirzepatide for Recovery and Alcohol Use Management

Endometrial Cancer (3)

NCT	Acronym	Phase	Status	Title
NCT07078838	—	P2	not yet recruiting	Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
NCT07065552	—	Early P1	recruiting	Tirzepatide in Obesity-Driven Endometrial Cancer
NCT06751589	—	Early P1	recruiting	A Study of a Weight Loss Intervention in People With Endometrial Cancer

Type 1 Diabetes (3)

NCT	Acronym	Phase	Status	Title
NCT07284511	TZP	P2/P3	recruiting	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
NCT06962280	SURPASS-T1D-2	P3	active not recruiting	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895	SURPASS-T1D-1	P3	active not recruiting	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Obesity and Obesity-related Medical Conditions (3)

NCT	Acronym	Phase	Status	Title
NCT06803888	—	P4	active not recruiting	Bariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06721507	—	P4	recruiting	2024 Tirzepatide-Bariatric Surgery
NCT06918405	—	P3	active not recruiting	Efficacy and Safety of Tirzepatide for Weight Management

Type 1 Diabetes Mellitus (2)

NCT	Acronym	Phase	Status	Title
NCT06180616	TZP-T1D	P2	not yet recruiting	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
NCT06820281	TIRTLE2	P2	not yet recruiting	Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes

Cannabis Use Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT07468552	—	P2	not yet recruiting	Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
NCT07265752	—	P2	not yet recruiting	Tirzepatide for the Treatment of Cannabis Use Disorder

Obesity & Overweight (2)

NCT	Acronym	Phase	Status	Title
NCT07298915	EXER-MED	P3	not yet recruiting	The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
NCT07382180	TIR-REAL	N/A	completed	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients

Obesity (Disorder) (2)

NCT	Acronym	Phase	Status	Title
NCT07257484	—	P4	not yet recruiting	Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
NCT07373834	TIRMO	N/A	recruiting	Tirzepatide and Muscle Outcomes in Obesity

Alcohol Use Disorder (2)

NCT	Acronym	Phase	Status	Title
NCT06939088	DUALPSYCHIATRY	P2	recruiting	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder
NCT06994338	—	P2	recruiting	Tirzepatide for Alcohol Use Disorder

Diabetes (2)

NCT	Acronym	Phase	Status	Title
NCT06759701	—	Early P1	recruiting	Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
NCT05990374	—	N/A	unknown	Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years

Psoriasis (2)

NCT	Acronym	Phase	Status	Title
NCT06857942	LY3298176	P4	recruiting	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
NCT06588283	TOGETHER-PsO	P3	active not recruiting	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Mild Autonomous Cortisol Secretion (MACS) (1)

NCT	Acronym	Phase	Status	Title
NCT07573163	—	P2	not yet recruiting	Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia (1)

NCT	Acronym	Phase	Status	Title
NCT07349641	—	P2	not yet recruiting	A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Heart Failure, Diastolic (1)

NCT	Acronym	Phase	Status	Title
NCT07554638	—	P4	not yet recruiting	Incretin Therapies in Obesity-related HFpEF

Atrial Fibrillation Ablation (1)

NCT	Acronym	Phase	Status	Title
NCT07382024	TREAT-AF	N/A	not yet recruiting	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation

Obesity-related Male Infertility (1)

NCT	Acronym	Phase	Status	Title
NCT07179120	—	P2	not yet recruiting	Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health

Overweight or Obesity; Type 2 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT07555730	AIM-MAINTAIN	P4	not yet recruiting	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)

Acute Lymphoblastic Leukemia (1)

NCT	Acronym	Phase	Status	Title
NCT07228741	—	P2	recruiting	Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (1)

NCT	Acronym	Phase	Status	Title
NCT07527910	—	P2	not yet recruiting	A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Obesity Prevention (1)

NCT	Acronym	Phase	Status	Title
NCT06811324	—	P2	recruiting	Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

Overweight , Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT07504172	TIRZ-DOSE-NL	N/A	not yet recruiting	Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Metabolic Alcohol-associated Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07046819	—	P2	recruiting	Tirzepatide in MetALD

Cardiovascular Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT07483801	DECODE	P4	not yet recruiting	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies

Psoriatic Arthritis (PsA) (1)

NCT	Acronym	Phase	Status	Title
NCT07443956	COMBAT-PsA	N/A	recruiting	Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis

Idiopathic Intracranial Hypertension (IIH) (1)

NCT	Acronym	Phase	Status	Title
NCT07191873	TIIHT	P4	not yet recruiting	Tirzepatide in Idiopathic Intracranial Hypertension Trial

Colorectal Cancer Prevention (1)

NCT	Acronym	Phase	Status	Title
NCT07095517	PROSPECT	P1	recruiting	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Hypertension (1)

NCT	Acronym	Phase	Status	Title
NCT07364175	SOLUTION-Pilot	N/A	recruiting	A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

Opioid Use Disorder (1)

NCT	Acronym	Phase	Status	Title
NCT06651177	TAB	P2	recruiting	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Prostate Carcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07202247	—	P2	recruiting	Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

Tirzepatide (1)

NCT	Acronym	Phase	Status	Title
NCT07423247	—	P4	recruiting	Tirzepatide (Spartina) in Obese Kidney Transplant Recipients

Polycystic Ovary Syndrome (PCOS) (1)

NCT	Acronym	Phase	Status	Title
NCT07326111	PERIODS	P4	recruiting	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese

Obesity &Amp; Overweight (1)

NCT	Acronym	Phase	Status	Title
NCT07245771	—	P1/P2	recruiting	Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity

Long COVID (1)

NCT	Acronym	Phase	Status	Title
NCT07128082	LOCITT	P2	active not recruiting	The Long COVID Treatment Trial

Metabolic Dysfunction-Associated Steatotic Liver Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07165028	—	P3	recruiting	A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Musculoskeletal Abnormalities (1)

NCT	Acronym	Phase	Status	Title
NCT07154719	GRAMS	P4	recruiting	GLP-1R Actions on Muscle and the Skeleton

Type2 Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT07203677	TIRZSITA-CVOT	N/A	completed	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)

Lipodystrophy, Partial (1)

NCT	Acronym	Phase	Status	Title
NCT07091734	TILT-2024	P2	recruiting	Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024

Type1diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT07096908	—	P4	recruiting	Tirzepatide Use in People With Obesity and Type 1 Diabetes

MASLD (1)

NCT	Acronym	Phase	Status	Title
NCT06934642	—	Early P1	recruiting	Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

Crohn's Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06937099	COMMIT-CD	P3	recruiting	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Ulcerative Colitis (1)

NCT	Acronym	Phase	Status	Title
NCT06937086	COMMIT-UC	P3	recruiting	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Adults With Simple Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT07293325	—	N/A	recruiting	Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Crohn Disease (CD) (1)

NCT	Acronym	Phase	Status	Title
NCT06976853	—	P2	recruiting	Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

Prader-Willi Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT06901245	—	P4	recruiting	Tirzepatide in PWS, HO and GNSO

Atrial Fibrillation (1)

NCT	Acronym	Phase	Status	Title
NCT06802081	TIRO-AF	P2	recruiting	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Autosomal Dominant Polycystic Kidney (1)

NCT	Acronym	Phase	Status	Title
NCT06582875	—	P2	recruiting	Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Crohn Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06774079	GLP-1 RA	P4	recruiting	Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

Type 1 Diabetes (T1D) (1)

NCT	Acronym	Phase	Status	Title
NCT06630585	AID-JUNCT	P3	recruiting	GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Heart Failure (1)

NCT	Acronym	Phase	Status	Title
NCT07303556	ICDDTKZ26	N/A	active not recruiting	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs

Type2diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT06648031	DehydraTECH	P1	completed	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants

Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06517212	TRIM-EBC	P2	recruiting	Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Type 2 Diabetes (Adult Onset) (1)

NCT	Acronym	Phase	Status	Title
NCT06246799	—	P3	recruiting	Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

Hormone Receptor-Positive Breast Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06518837	FITWISE	P2	recruiting	Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Severe Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06162715	GRABS-0	P2/P3	enrolling by invitation	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial

Coronary Artery Disease (1)

NCT	Acronym	Phase	Status	Title
NCT06606821	IDEAL-COR	P4	recruiting	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

Overweight and Obesity (1)

NCT	Acronym	Phase	Status	Title
NCT06445075	EMBRAZE	P2	completed	Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese

Hidradenitis Suppurativa (1)

NCT	Acronym	Phase	Status	Title
NCT06301256	—	N/A	unknown	Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa

Type II Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05708859	T-PLAQUE	P4	recruiting	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Wolfram Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT05659368	—	P2	unknown	Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1

Chronic Kidney Disease stage3 (1)

NCT	Acronym	Phase	Status	Title
NCT07309094	ADIPO-CKD	N/A	recruiting	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Metabolic Health (1)

NCT	Acronym	Phase	Status	Title
NCT06354101	—	N/A	withdrawn	The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

Healthy Subjects (1)

NCT	Acronym	Phase	Status	Title
NCT05822544	—	P1	recruiting	Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

Diabetes Type 2 (1)

NCT	Acronym	Phase	Status	Title
NCT05691712	SURPASS-CN-INS	P3	completed	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes

Weight Loss (1)

NCT	Acronym	Phase	Status	Title
NCT05766358	EXPEND-FU	N/A	completed	Role Of Metabolic Adaptation In Weight Regain

Obstructive Sleep Apnea (1)

NCT	Acronym	Phase	Status	Title
NCT05412004	SURMOUNT-OSA	P3	completed	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

Type2 Diabetes (1)

NCT	Acronym	Phase	Status	Title
NCT05260021	SURPASS-PEDS	P3	completed	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

Nonalcoholic Steatohepatitis (1)

NCT	Acronym	Phase	Status	Title
NCT04166773	SYNERGY-NASH	P2	completed	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

Hepatic Insufficiency (1)

NCT	Acronym	Phase	Status	Title
NCT03940742	—	P1	completed	A Study of Tirzepatide in Participants With Impaired Liver Function

Renal Insufficiency (1)

NCT	Acronym	Phase	Status	Title
NCT03482024	LY3298176	P1	completed	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function

Tirzepatide pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
STOP KNEE-OA	NCT06191848	P4	recruiting	Obesity	352	—
LY3298176	NCT07247084	P4	recruiting	Obesity	3,000	—
PERIODS	NCT07326111	P4	recruiting	Polycystic Ovary Syndrome (PCOS)	198	—
AIM-MAINTAIN	NCT07555730	P4	not yet recruiting	Overweight or Obesity; Type 2 Diabetes	400	—
IDEAL-COR	NCT06606821	P4	recruiting	Coronary Artery Disease	124	PMID 24060894
LY3298176	NCT06857942	P4	recruiting	Psoriasis	200	—
DECODE	NCT07483801	P4	not yet recruiting	Cardiovascular Diseases	112	—
TIIHT	NCT07191873	P4	not yet recruiting	Idiopathic Intracranial Hypertension (IIH)	60	PMID 25449938
SURPASS-EARLY	NCT05433584	P4	active not recruiting	Type 2 Diabetes	780	—
LY3298176	NCT07438444	P4	recruiting	Diabetes Mellitus, Type 2	344	—
GRAMS	NCT07154719	P4	recruiting	Musculoskeletal Abnormalities	50	PMID 33951361
GLP-1 RA	NCT06774079	P4	recruiting	Crohn Disease	24	—
GLOW	NCT06861439	P4	active not recruiting	Obesity	40	—
T-PLAQUE	NCT05708859	P4	recruiting	Type II Diabetes	120	—
T-RAM	NCT06635057	P4	completed	Type 2 Diabetes	166	—
SURPASS-SWITCH	NCT05564039	P4	completed	Type 2 Diabetes	282	PMID 41912265
TRZ	NCT06009653	P4	withdrawn	Obesity	0	—
LY3298176	NCT05706506	P4	completed	Type 2 Diabetes	152	—
SURMOUNT-ADOLESCENTS-2	NCT06439277	P3	recruiting	Obesity	300	—
LY3298176	NCT06075667	P3	active not recruiting	Obesity	150	—
COMMIT-CD	NCT06937099	P3	recruiting	Crohn's Disease	290	—
COMMIT-UC	NCT06937086	P3	recruiting	Ulcerative Colitis	350	—
SURMOUNT-1	NCT07481747	P3	recruiting	Obesity	2,539	—
SURMOUNT-MMO	NCT05556512	P3	active not recruiting	Obesity	15,374	—
SURPASS-T1D-2	NCT06962280	P3	active not recruiting	Type 1 Diabetes	465	—
EXER-MED	NCT07298915	P3	not yet recruiting	Obesity & Overweight	24	—
SURPASS-T1D-1	NCT06914895	P3	active not recruiting	Type 1 Diabetes	905	—
TRIUMPH-5	NCT06662383	P3	active not recruiting	Obesity	800	—
REIMAGINE 5	NCT06534411	P3	active not recruiting	Diabetes Mellitus, Type 2	1,023	—
AID-JUNCT	NCT06630585	P3	recruiting	Type 1 Diabetes (T1D)	42	—
TOGETHER-PsO	NCT06588283	P3	active not recruiting	Psoriasis	250	—
TOGETHER-PsA	NCT06588296	P3	completed	Psoriatic Arthritis	279	—
SURPASS-CVOT	NCT04255433	P3	completed	Type 2 Diabetes Mellitus	13,299	PMID 41903177
SURPASS-PEDS	NCT05260021	P3	completed	Type2 Diabetes	99	PMID 40975112
SURMOUNT-5	NCT05822830	P3	completed	Obesity	751	PMID 40980721
LY3298176	NCT05963022	P3	completed	Type 2 Diabetes	206	—
SURMOUNT-1	NCT04184622	P3	completed	Overweight	2,539	PMID 40550133
LY3298176	NCT04847557	P3	completed	Obesity	731	PMID 39556714
SURPASS-CN-INS	NCT05691712	P3	completed	Diabetes Type 2	257	PMID 41167231
SURMOUNT-OSA	NCT05412004	P3	completed	Obstructive Sleep Apnea	469	PMID 38912654
SURMOUNT-J	NCT04844918	P3	completed	Obesity	267	PMID 41290555
SURMOUNT-4	NCT04660643	P3	completed	Obesity	783	PMID 41284285
SURMOUNT-3	NCT04657016	P3	completed	Obesity	579	PMID 41537305
SURMOUNT-2	NCT04657003	P3	completed	Type 2 Diabetes	938	PMID 40120035
SURMOUNT-CN	NCT05024032	P3	completed	Obesity	210	PMID 38819983
SURPASS-6	NCT04537923	P3	completed	Type 2 Diabetes	1,428	PMID 37786396
LY3298176	NCT04093752	P3	completed	Type 2 Diabetes	917	PMID 37231074
SURPASS-4	NCT03730662	P3	completed	Type 2 Diabetes Mellitus	2,002	PMID 36152639
SURPASS J-mono	NCT03861052	P3	completed	Type 2 Diabetes	636	PMID 38310163
LY3298176	NCT03861039	P3	completed	Type 2 Diabetes Mellitus	443	PMID 35914542
SURPASS-2	NCT03987919	P3	completed	Type 2 Diabetes	1,879	PMID 37000390
SURPASS-5	NCT04039503	P3	completed	Type 2 Diabetes	475	PMID 35133415
SURPASS-3	NCT03882970	P3	completed	Type 2 Diabetes Mellitus	1,444	PMID 40318682
SURPASS-1	NCT03954834	P3	completed	Type 2 Diabetes Mellitus	478	PMID 34186022
TRIM-EBC	NCT06517212	P2	recruiting	Breast Cancer	48	—
TILT-2024	NCT07091734	P2	recruiting	Lipodystrophy, Partial	32	—
TZP-T1D	NCT06180616	P2	not yet recruiting	Type 1 Diabetes Mellitus	40	PMID 40962353
DUALPSYCHIATRY	NCT06939088	P2	recruiting	Alcohol Use Disorder	108	—
LY900038	NCT06143956	P2	recruiting	Obesity	1,481	—
CBT	NCT07292519	P2	not yet recruiting	Alcohol Use Disorder (AUD)	46	—
TIRTLE2	NCT06820281	P2	not yet recruiting	Type 1 Diabetes Mellitus	44	—
LIBERATE	NCT06847399	P2	recruiting	Obesity and Overweight	105	—
TAB	NCT06651177	P2	recruiting	Opioid Use Disorder	310	—
FITWISE	NCT06518837	P2	recruiting	Hormone Receptor-Positive Breast Cancer	40	—
GYMINDA	NCT06965413	P2	active not recruiting	Obesity	285	—
TIRO-AF	NCT06802081	P2	recruiting	Atrial Fibrillation	100	—
LY3985863	NCT06643728	P2	active not recruiting	Obesity	252	—
LOCITT	NCT07128082	P2	active not recruiting	Long COVID	1,000	—
LY3298176	NCT06037252	P2	active not recruiting	Type 2 Diabetes	414	—
TREASURE-CKD	NCT05536804	P2	active not recruiting	Overweight	140	PMID 39963952
LY3298176	NCT06603571	P2	active not recruiting	Obesity	350	—
STREAM	NCT06727331	P2	recruiting	Alcohol Use Disorder (AUD)	20	—
LY3298176	NCT06373146	P2	completed	Obesity	392	—
TABFAT	NCT06893211	P2	active not recruiting	Obesity	35	PMID 40847412
EMBRAZE	NCT06445075	P2	completed	Overweight and Obesity	102	—
LY3985863	NCT06901349	P2	withdrawn	Obesity	0	—
BMT-801	NCT06565611	P2	active not recruiting	Obesity	108	—
STRIDES	NCT06515418	P2	terminated	Obesity	204	—
SYNERGY-NASH	NCT04166773	P2	completed	Nonalcoholic Steatohepatitis	190	PMID 38856224
LY3298176	NCT03131687	P2	completed	Type 2 Diabetes Mellitus	318	PMID 35210595
LY3298176	NCT03311724	P2	completed	Type 2 Diabetes	111	—

Terminated and withdrawn Tirzepatide trials (4)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06901349withdrawnA Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
NCT06515418terminatedEfficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over
NCT06009653withdrawnEffects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity
NCT06354101withdrawnThe Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.

All Tirzepatide trials (190)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06191848	STOP KNEE-OA	Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)	P4	recruiting	352	University of Melbourne	Nov 2024
NCT07165028		A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)	P3	recruiting	4,500	Eli Lilly and Company	Oct 2025
NCT07247084	LY3298176	A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)	P4	recruiting	3,000	Eli Lilly and Company	Nov 2025
NCT07559500	AUD	Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)	P1	recruiting	176	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	May 2026
NCT06517212	TRIM-EBC	Tirzepatide Weight Loss for MRD+ Early Breast Cancer	P2	recruiting	48	Baylor Research Institute	Nov 2024
NCT06439277	SURMOUNT-ADOLESCENTS-2	A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)	P3	recruiting	300	Eli Lilly and Company	Jun 2024
NCT07443956	COMBAT-PsA	Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis	N/A	recruiting	45	NHS Greater Glasgow and Clyde	Mar 2026
NCT07554638		Incretin Therapies in Obesity-related HFpEF	P4	not yet recruiting	50	Columbia University	Jun 2026
NCT07349641		A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer	P2	not yet recruiting	55	National Cancer Institute (NCI)	Jul 2026
NCT07326111	PERIODS	A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese	P4	recruiting	198	University of Bonn	Dec 2025
NCT05912621		Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity	P2	recruiting	66	Stanford University	Nov 2023
NCT07527910		A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD	P2	not yet recruiting	204	Regeneron Pharmaceuticals	Apr 2026
NCT07091734	TILT-2024	Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024	P2	recruiting	32	University of Michigan	Sep 2025
NCT06075667	LY3298176	A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	P3	active not recruiting	150	Eli Lilly and Company	Oct 2023
NCT06582875		Glucagon-Like Peptide-1 Receptor Agonist in ADPKD	P2	recruiting	126	University of Colorado, Denver	Mar 2025
NCT06246799		Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes	P3	recruiting	256	The University of Texas Health Science Center at San Antonio	Nov 2024
NCT07567378	CARTIZ	CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry	—	not yet recruiting	30	JULIO GRANADOS MONTIEL	May 2026
NCT07078838		Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer	P2	not yet recruiting	40	UNC Lineberger Comprehensive Cancer Center	Aug 2026
NCT05933499		Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity	P2	recruiting	63	Massachusetts General Hospital	Nov 2025
NCT07364175	SOLUTION-Pilot	A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults	N/A	recruiting	60	Cambridge University Hospitals NHS Foundation Trust	Jan 2026
NCT07284511	TZP	A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar	P2/P3	recruiting	105	McGill University Health Centre/Research Institute of the McGill University Health Centre	May 2026
NCT06180616	TZP-T1D	Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity	P2	not yet recruiting	40	Royal North Shore Hospital	Dec 2026
NCT07573163		Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion	P2	not yet recruiting	34	Alaa Sada	Jul 2026
NCT07095517	PROSPECT	Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors	P1	recruiting	20	Massachusetts General Hospital	Feb 2026
NCT06759701		Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study	Early P1	recruiting	30	M.D. Anderson Cancer Center	Jul 2025
NCT06939088	DUALPSYCHIATRY	Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder	P2	recruiting	108	Anders Fink-Jensen, MD, DMSci	May 2025
NCT07309094	ADIPO-CKD	Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	—	recruiting	250	Cardenal Herrera University	Sep 2023
NCT07228741		Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity	P2	recruiting	20	St. Jude Children's Research Hospital	Apr 2026
NCT07468552		Trial of Tirzepatide for the Treatment of Cannabis Use Disorder	P2	not yet recruiting	100	National Institute on Drug Abuse (NIDA)	Nov 2026
NCT07555730	AIM-MAINTAIN	AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)	P4	not yet recruiting	400	Huazhong University of Science and Technology	Apr 2026
NCT06976853		Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease	P2	recruiting	60	Washington University School of Medicine	May 2025
NCT07096908		Tirzepatide Use in People With Obesity and Type 1 Diabetes	P4	recruiting	60	Dasman Diabetes Institute	Jul 2025
NCT06606821	IDEAL-COR	The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease	P4	recruiting	124	Tina Vilsbøll	Oct 2024
NCT07382024	TREAT-AF	Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation	N/A	not yet recruiting	200	National Taiwan University Hospital	May 2026
NCT07065552		Tirzepatide in Obesity-Driven Endometrial Cancer	Early P1	recruiting	20	UNC Lineberger Comprehensive Cancer Center	Apr 2026
NCT07265752		Tirzepatide for the Treatment of Cannabis Use Disorder	P2	not yet recruiting	6	Brigham and Women's Hospital	Jul 2026
NCT06937099	COMMIT-CD	Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight	P3	recruiting	290	Eli Lilly and Company	Jun 2025
NCT06857942	LY3298176	A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)	P4	recruiting	200	Eli Lilly and Company	Mar 2025
NCT07483801	DECODE	DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies	P4	not yet recruiting	112	Cambridge University Hospitals NHS Foundation Trust	Mar 2026
NCT06937086	COMMIT-UC	Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study	P3	recruiting	350	Eli Lilly and Company	Jun 2025
NCT07202247		Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial	P2	recruiting	60	City of Hope Medical Center	Jan 2026
NCT06801015		Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions	P4	active not recruiting	30	Mayo Clinic	Oct 2025
NCT07481747	SURMOUNT-1	Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)	P3	recruiting	2,539	Hudson Biotech	Feb 2026
NCT07463846		A Study to Evaluate ALN-2232 in Participants With Obesity	P1/P2	recruiting	156	Alnylam Pharmaceuticals	Mar 2026
NCT07191873	TIIHT	Tirzepatide in Idiopathic Intracranial Hypertension Trial	P4	not yet recruiting	60	Duke University	Feb 2026
NCT06143956	LY900038	A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight	P2	recruiting	1,481	Eli Lilly and Company	Nov 2023
NCT06700538		A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus	P1/P2	recruiting	180	Arrowhead Pharmaceuticals	Dec 2024
NCT07292519	CBT	Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)	P2	not yet recruiting	46	South West Sydney Local Health District	Jan 2026
NCT06820281	TIRTLE2	Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes	P2	not yet recruiting	44	Victor Chang Cardiac Research Institute	Jul 2026
NCT06751589		A Study of a Weight Loss Intervention in People With Endometrial Cancer	Early P1	recruiting	36	Memorial Sloan Kettering Cancer Center	Dec 2024
NCT07257484		Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors	P4	not yet recruiting	30	Weill Medical College of Cornell University	Apr 2026
NCT06732245		Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese	P2	not yet recruiting	224	Biomed Industries, Inc.	Aug 2026
NCT06657209		Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide	P4	recruiting	104	Stanford University	Jan 2025
NCT06847399	LIBERATE	Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder	P2	recruiting	105	Johns Hopkins University	Sep 2025
NCT06803888		Bariatric Surgery vs. Semaglutide vs. Tirzepatide	P4	active not recruiting	125	Ali Aminian	Jan 2025
NCT06162715	GRABS-0	GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial	P2/P3	enrolling by invitation	30	Vanderbilt University Medical Center	Oct 2024
NCT06864026		A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	P4	recruiting	200	Eli Lilly and Company	Mar 2025
NCT05433584	SURPASS-EARLY	A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	P4	active not recruiting	780	Eli Lilly and Company	Aug 2022
NCT07492563		Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay	—	not yet recruiting	300	LABORATORIOS INDUFAR	Mar 2026
NCT07438444	LY3298176	A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity	P4	recruiting	344	Eli Lilly and Company	Feb 2026
NCT06651177	TAB	Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder	P2	recruiting	310	T. John Winhusen, PhD	Jan 2026
NCT05556512	SURMOUNT-MMO	A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	P3	active not recruiting	15,374	Eli Lilly and Company	Oct 2022
NCT05553093		Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes	P4	recruiting	150	Nanjing First Hospital, Nanjing Medical University	Mar 2022
NCT06518837	FITWISE	Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer	P2	recruiting	40	Rutgers, The State University of New Jersey	Oct 2024
NCT07218445		The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity	P4	recruiting	40	Mayo Clinic	Apr 2026
NCT07245771		Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity	P1/P2	recruiting	104	Ikaria Bioscience Pty Ltd	Nov 2025
NCT06962280	SURPASS-T1D-2	A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	P3	active not recruiting	465	Eli Lilly and Company	May 2025
NCT07521631		Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes	P2	recruiting	372	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	Mar 2026
NCT06965413	GYMINDA	A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity	P2	active not recruiting	285	Hoffmann-La Roche	May 2025
NCT07298915	EXER-MED	The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)	P3	not yet recruiting	24	University of Virginia	Aug 2026
NCT07293325		Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity	N/A	recruiting	66	Second Affiliated Hospital, School of Medicine, Zhejiang University	Jun 2025
NCT06811324		Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults	P2	recruiting	20	The University of Texas Health Science Center at San Antonio	Apr 2026
NCT06802081	TIRO-AF	TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation	P2	recruiting	100	The Cleveland Clinic	Apr 2025
NCT07000955		Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity	P1/P2	active not recruiting	98	Innovent Biologics (Suzhou) Co. Ltd.	Jun 2025
NCT07154719	GRAMS	GLP-1R Actions on Muscle and the Skeleton	P4	recruiting	50	Pennington Biomedical Research Center	Oct 2025
NCT07373834	TIRMO	Tirzepatide and Muscle Outcomes in Obesity	N/A	recruiting	30	University Medical Centre Ljubljana	Jan 2026
NCT07057310		Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women	P4	enrolling by invitation	30	Mayo Clinic	May 2025
NCT06774079	GLP-1 RA	Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients	P4	recruiting	24	University of Miami	Mar 2025
NCT06643728	LY3985863	A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight	P2	active not recruiting	252	Eli Lilly and Company	Oct 2024
NCT07179120		Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health	P2	not yet recruiting	180	First Affiliated Hospital of Wenzhou Medical University	May 2026
NCT07319975		Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity	N/A	not yet recruiting	48	Istanbul Galata University	Dec 2025
NCT07128082	LOCITT	The Long COVID Treatment Trial	P2	active not recruiting	1,000	Scripps Translational Science Institute	Oct 2025
NCT06861439	GLOW	GLP-1s to Enhance Lasting Optimal Weight	P4	active not recruiting	40	Wake Forest University Health Sciences	Jul 2025
NCT06901245		Tirzepatide in PWS, HO and GNSO	P4	recruiting	36	Grace Kim	May 2025
NCT06914895	SURPASS-T1D-1	A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	P3	active not recruiting	905	Eli Lilly and Company	Apr 2025
NCT06721507		2024 Tirzepatide-Bariatric Surgery	P4	recruiting	50	Marlene Starr	Mar 2025
NCT06662383	TRIUMPH-5	A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity	P3	active not recruiting	800	Eli Lilly and Company	Nov 2024
NCT07299084		A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus	P1	active not recruiting	40	Eli Lilly and Company	Jan 2026
NCT07303556	ICDDTKZ26	Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs	N/A	active not recruiting	120	Nazarbayev University	Dec 2024
NCT06037252	LY3298176	A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity	P2	active not recruiting	414	Eli Lilly and Company	Sep 2023
NCT05536804	TREASURE-CKD	A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes	P2	active not recruiting	140	Eli Lilly and Company	Feb 2023
NCT06980623		Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction	—	active not recruiting	26,000	Brigham and Women's Hospital	Jan 2025
NCT07423247		Tirzepatide (Spartina) in Obese Kidney Transplant Recipients	P4	recruiting	30	Shahid Beheshti University of Medical Sciences	Jan 2026
NCT06994338		Tirzepatide for Alcohol Use Disorder	P2	recruiting	42	University of Southern California	Oct 2025
NCT06934642		Effect of Tirzepatide on Markers of MASLD in Patients With Obesity	Early P1	recruiting	8	University of New Mexico	Jun 2025
NCT06603571	LY3298176	A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes	P2	active not recruiting	350	Eli Lilly and Company	Sep 2024
NCT07504172	TIRZ-DOSE-NL	Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity	—	not yet recruiting	1,700	Radboud University Medical Center	Apr 2026
NCT06935838		Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV	P2	recruiting	12	University of Hawaii	Nov 2025
NCT07099742	T2DM	Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)	—	not yet recruiting	364	Dr. Md. Alimur Reza	Sep 2025
NCT06727331	STREAM	Study of Tirzepatide for Recovery and Alcohol Use Management	P2	recruiting	20	Brigham and Women's Hospital	Sep 2025
NCT07046819		Tirzepatide in MetALD	P2	recruiting	120	National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Apr 2026
NCT06534411	REIMAGINE 5	A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both	P3	active not recruiting	1,023	Novo Nordisk A/S	Nov 2024
NCT06630585	AID-JUNCT	GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes	P3	recruiting	42	University of Bern	Feb 2025
NCT06918405		Efficacy and Safety of Tirzepatide for Weight Management	P3	active not recruiting	440	Chittagong Medical College	Jan 2025
NCT05822544		Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes	P1	recruiting	564	OrsoBio, Inc	Apr 2023
NCT06737042		Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants	P2	not yet recruiting	285	Gan and Lee Pharmaceuticals, USA	Feb 2025
NCT06588283	TOGETHER-PsO	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight	P3	active not recruiting	250	Eli Lilly and Company	Sep 2024
NCT05708859	T-PLAQUE	Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT	P4	recruiting	120	Matthew J. Budoff	Jan 2024
NCT07417618	INTERCEPT	INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)	—	active not recruiting	60,000	Brigham and Women's Hospital	Jan 2026
NCT07176663	Tirzepatide	Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure	N/A	not yet recruiting	15	Shahid Beheshti University of Medical Sciences	Feb 2026
NCT06588296	TOGETHER-PsA	Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight	P3	completed	279	Eli Lilly and Company	Sep 2024
NCT06635057	T-RAM	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan	P4	completed	166	Eli Lilly and Company	Oct 2024
NCT06221969		A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor	P3	completed	1,024	Novo Nordisk A/S	Jan 2024
NCT06373146	LY3298176	A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity	P2	completed	392	Eli Lilly and Company	Apr 2024
NCT06745128		Tirzepatide for Obesity and Meth Use Disorder	P2	active not recruiting	45	University of Texas Southwestern Medical Center	Feb 2025
NCT06485089		Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers	—	completed	25	University of Kansas Medical Center	Sep 2024
NCT06779929	SURPASS CVOT	Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	—	completed	70,000	Brigham and Women's Hospital	Nov 2024
NCT05756764		Anti-obesity Pharmacotherapy and Inflammation	—	active not recruiting	30	Louisiana State University Health Sciences Center in New Orleans	Jun 2023
NCT06047548		A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities	P3	completed	441	Eli Lilly and Company	Sep 2023
NCT06916065	LY3841136	A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity	P1	completed	188	Eli Lilly and Company	Apr 2025
NCT07382180	TIR-REAL	Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients	—	completed	254	Azienda Sanitaria Locale Napoli 2 Nord	Feb 2025
NCT06911203		A Study of BGM0504 in Participants With Obesity	P2	recruiting	90	BrightGene Bio-Medical Technology Co., Ltd.	Apr 2025
NCT06131437		A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight	P3	completed	809	Novo Nordisk A/S	Nov 2023
NCT06893211	TABFAT	Effect of Tirzepatide on Brown Adipose Tissue in Obesity	P2	active not recruiting	35	University Medical Centre Ljubljana	Mar 2025
NCT06297616		A Study of LY3841136 in Japanese Participants With Obesity or Overweight	P1	completed	128	Eli Lilly and Company	Apr 2024
NCT07203677	TIRZSITA-CVOT	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)	—	completed	49,065	Brigham and Women's Hospital	Sep 2025
NCT06345066		A Study of LY3841136 in Overweight and Obese Participants	P1	completed	96	Eli Lilly and Company	Apr 2024
NCT06890611	LY3985863	A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants	P1	completed	125	Eli Lilly and Company	Mar 2025
NCT06648031	DehydraTECH	Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants	P1	completed	148	Lexaria Bioscience Corp.	Dec 2024
NCT07088718	DUP-SURPASS	Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data	—	completed	44,671	Brigham and Women's Hospital	Oct 2024
NCT07096063	TIRZSEMA-CVOT	Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk	—	completed	887,132	Brigham and Women's Hospital	Oct 2024
NCT06445075	EMBRAZE	Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese	P2	completed	102	Scholar Rock, Inc.	May 2024
NCT04255433	SURPASS-CVOT	A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes	P3	completed	13,299	Eli Lilly and Company	May 2020
NCT06901349	LY3985863	A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes	P2	withdrawn	0	Eli Lilly and Company	May 2025
NCT06914154	DUP-SUMMIT	Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data	—	completed	11,265	Brigham and Women's Hospital	Jan 2025
NCT06914141	DUP-TIRZSEMA	Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction	—	completed	28,118	Brigham and Women's Hospital	Jan 2025
NCT06326060		A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Help People With Excess Body Weight Lose Weight	P2	completed	354	Novo Nordisk A/S	Mar 2024
NCT06565611	BMT-801	A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity	P2	active not recruiting	108	Palatin Technologies, Inc	Aug 2024
NCT06301256		Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa	N/A	unknown	20	Florida Academic Centers Research and Education, LLC	Mar 2024
NCT06515418	STRIDES	Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over	P2	terminated	204	BioAge Labs, Inc.	Jun 2024
NCT05260021	SURPASS-PEDS	A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both	P3	completed	99	Eli Lilly and Company	Apr 2022
NCT05696847	LY3298176	A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity	P1	completed	28	Eli Lilly and Company	Feb 2023
NCT05659368		Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1	P2	unknown	10	Ospedale San Raffaele	Jan 2024
NCT05822830	SURMOUNT-5	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	P3	completed	751	Eli Lilly and Company	Apr 2023
NCT05963022	LY3298176	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)	P3	completed	206	Eli Lilly and Company	Aug 2023
NCT05564039	SURPASS-SWITCH	A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)	P4	completed	282	Eli Lilly and Company	Nov 2022
NCT04184622	SURMOUNT-1	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight	P3	completed	2,539	Eli Lilly and Company	Dec 2019
NCT04847557	LY3298176	A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial	P3	completed	731	Eli Lilly and Company	Apr 2021
NCT05691712	SURPASS-CN-INS	A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes	P3	completed	257	Eli Lilly and Company	Feb 2023
NCT06009653	TRZ	Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	P4	withdrawn	0	Washington University School of Medicine	Sep 2023
NCT05766358	EXPEND-FU	Role Of Metabolic Adaptation In Weight Regain	—	completed	27	Pennington Biomedical Research Center	Oct 2022
NCT05412004	SURMOUNT-OSA	Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea	P3	completed	469	Eli Lilly and Company	Jun 2022
NCT05978713	LY3298176	A Study of Tirzepatide (LY3298176) in Healthy Lactating Females	P1	completed	11	Eli Lilly and Company	Jul 2023
NCT04166773	SYNERGY-NASH	A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)	P2	completed	190	Eli Lilly and Company	Nov 2019
NCT05990374		Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years	N/A	unknown	100	Nanjing First Hospital, Nanjing Medical University	Aug 2023
NCT05706506	LY3298176	A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	P4	completed	152	Eli Lilly and Company	Mar 2023
NCT05810597		A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices	P1	completed	65	Eli Lilly and Company	Apr 2023
NCT06354101		The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.	—	withdrawn	0	CorEvitas	Jul 2023
NCT04844918	SURMOUNT-J	A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease	P3	completed	267	Eli Lilly and Company	May 2021
NCT05582096		A Study of LY3457263 in Obese Participants	P1	completed	38	Eli Lilly and Company	Nov 2022
NCT04660643	SURMOUNT-4	A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss	P3	completed	783	Eli Lilly and Company	Mar 2021
NCT04657016	SURMOUNT-3	A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program	P3	completed	579	Eli Lilly and Company	Mar 2021
NCT04657003	SURMOUNT-2	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight	P3	completed	938	Eli Lilly and Company	Mar 2021
NCT05024032	SURMOUNT-CN	A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)	P3	completed	210	Eli Lilly and Company	Sep 2021
NCT04311411		A Study of Tirzepatide in Overweight and Very Overweight Participants	P1	completed	114	Eli Lilly and Company	Aug 2020
NCT04537923	SURPASS-6	A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin	P3	completed	1,428	Eli Lilly and Company	Oct 2020
NCT04081337		A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide	P1	completed	55	Eli Lilly and Company	Jul 2020
NCT04050553		A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus	P1	completed	42	Eli Lilly and Company	Feb 2020
NCT04093752	LY3298176	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)	P3	completed	917	Eli Lilly and Company	Dec 2019
NCT04235959		A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus	P1	completed	24	Eli Lilly and Company	Oct 2020
NCT03730662	SURPASS-4	A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk	P3	completed	2,002	Eli Lilly and Company	Nov 2018
NCT03951753	T2DM	A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)	P1	completed	117	Eli Lilly and Company	Jun 2019
NCT03861052	SURPASS J-mono	A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes	P3	completed	636	Eli Lilly and Company	May 2019
NCT03861039	LY3298176	A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	P3	completed	443	Eli Lilly and Company	Mar 2019
NCT03987919	SURPASS-2	A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes	P3	completed	1,879	Eli Lilly and Company	Jul 2019
NCT04172987		A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants	P1	completed	40	Eli Lilly and Company	Feb 2020
NCT04039503	SURPASS-5	A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin	P3	completed	475	Eli Lilly and Company	Aug 2019
NCT04407234		A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide	P1	completed	36	Eli Lilly and Company	Sep 2020
NCT03882970	SURPASS-3	A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes	P3	completed	1,444	Eli Lilly and Company	Apr 2019
NCT03954834	SURPASS-1	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone	P3	completed	478	Eli Lilly and Company	Jun 2019
NCT04311424		Study of Tirzepatide in Healthy Participants	P1	completed	6	Eli Lilly and Company	Jul 2020
NCT03940742		A Study of Tirzepatide in Participants With Impaired Liver Function	P1	completed	32	Eli Lilly and Company	Jul 2019
NCT04050670		A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes	P1	completed	54	Eli Lilly and Company	Sep 2019
NCT04004988		A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants	P1	completed	47	Eli Lilly and Company	Aug 2019
NCT03482024	LY3298176	A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function	P1	completed	45	Eli Lilly and Company	Mar 2018
NCT03375463	LY3298176	A Study of Tirzepatide (LY3298176) in Healthy Participants	P1	completed	52	Eli Lilly and Company	Dec 2017
NCT03322631	LY3298176	A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes	P1	completed	48	Eli Lilly and Company	Nov 2017
NCT03131687	LY3298176	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus	P2	completed	318	Eli Lilly and Company	May 2017
NCT03311724	LY3298176	A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes	P2	completed	111	Eli Lilly and Company	Oct 2017
NCT02759107	LY3298176	A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)	P1	completed	142	Eli Lilly and Company	May 2016

Tirzepatide clinical trials: frequently asked questions

How many Tirzepatide clinical trials are there?: 190 Tirzepatide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 63 are actively recruiting participants. 68 are marked completed.
Are Tirzepatide clinical trials recruiting in 2026?: Yes — 63 Tirzepatide trials are actively recruiting in 2026, with 394 U.S. sites across 42 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Tirzepatide being studied for?: Tirzepatide is being studied for Obesity, Overweight, Type 2 Diabetes, Diabetes Mellitus, Type 2, Healthy and 166 more. The trials are grouped by indication on this page.
What phase is Tirzepatide in?: Tirzepatide clinical trials span 31 Phase 4, 42 Phase 3, 51 Phase 2, 28 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Tirzepatide clinical trials?: The lead sponsor across the most Tirzepatide trials is Eli Lilly and Company, with 89 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Tirzepatideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Tirzepatide overview Tirzepatide evidence & publications